Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Obesity

New weight-loss pill could reach UK by next year, says Mounjaro boss

Eli Lilly’s new pill could offer an easier path to weight loss for needle-averse patients

The Independent UK

Dining across the divide: ‘The one thing we bonded over was despising Reform’

A medical charity worker and an oncologist delved into the NHS, obesity and assisted dying. But could they agree on hiring doctors from abroad?

The Guardian - UK

Weight-loss jabs are not enough to tackle the obesity crisis, experts warn

THE UK’S OBESITY CHALLENGE : Weight-loss drug Mounjaro will be rolled out to a quarter of a million NHS patients. But leading experts tell Rebecca Thomas and Alicja Hagopian that weight-loss jabs alone will not be enough to solve the obesity crisis

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

On Thursday, Skye Bioscience Inc. (NASDAQ:SKYE) reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.

Benzinga

WHO Backs Weight-loss Drugs, Urges Cheap Generics

The World Health Organization recommended a range of blockbuster weight-loss drugs to treat diabetes and obesity globally for the first time on Friday, calling for cheap generic versions to be made available for people in developing countries.

International Business Times

Thousands of people who could benefit from weight loss jab denied access on the NHS

Wes Streeting pledged to do more to prevent people being ‘priced out’ of accessing weight-loss jabs

The Independent UK

Mapped: NHS patients facing postcode lottery for weight-loss jab Mounjaro

It’s estimated that 3.4 million people in the UK could benefit from taking a weight-loss jab like Mounjaro

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

‘No place in children’s hands’: under-16s in England to be banned from buying energy drinks

Government to ban sale of energy drinks with more than 150mg of caffeine, citing concerns over obesity and lack of concentration

The Guardian - UK

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Benzinga

Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes.

Benzinga

How more weight-loss jabs could save the country £53 billion a year

IN FULL

The Independent UK

True cost of the UK’s obesity crisis revealed – and how weight-loss jabs could be the answer

SPECIAL REPORT: The UK has an obesity epidemic, with levels having doubled since the 1990s. Could increasing the rollout of weight-loss drugs ease the burden on the overstretched NHS? Alicja Hagopian and Rebecca Thomas report

The Independent UK

Weight-loss drugs are a quick fix with long-term results

THE INDEPENDENT VIEW: Editorial: For those able to take them, weight-loss drugs can offer startling results in improved quality of life, and in relieving the pressure on the NHS and the British economy

The Independent UK

OPINION - The soaring price of weight loss drugs could derail the NHS's obesity plan – unless they take this action

The list price for the most popular and effective weight loss injection (Mounjaro) in the UK has risen by almost three times, from £122 to £330 a month for the highest dose, as of September 1.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times UK

Ozempic For Pets: New Drug Being Tested For Animal Obesity - Here's What We Know

Scientists test OKV-119, a six-month implant dubbed 'Ozempup', as a new Ozempic for pets to fight obesity in cats and dogs amid rising pet health risks.

The Independent UK

Deadline set for manufacturers to cut sugar and salt in baby food

New data shows that more than two thirds of children aged 18 months to three years are eating too much sugar

Evening Standard

Manufacturers given 18 months to cut sugar and salt in baby food products

New labelling guidelines will also help parents make informed choices about what they feed their children.

The Guardian - UK

Obesity has a serious impact on health – it shortened my mum’s life

Letter: Blaming the patriarchy, fatphobia or big pharma doesn’t reduce the risks of being overweight, says Frances Knight

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

Benzinga

Palantir, AMD, Oracle, Viking And Nvidia: Why These 5 Stocks Are On Investors' Radars Today

U.S. stock indices closed mixed on Tuesday, with the Dow Jones Industrial Average edging up 0.02% to 44,922.27. The SP 500 slipped 0.6% to 6,411.37, while the Nasdaq saw a steeper drop, tumbling nearly 1.5% to 21,314.95.These are the top stocks that gained the attention of retail traders and investors…

International Business Times UK

Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

Benzinga

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill.

Benzinga

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.

The Guardian - UK

Puppy fat implants: are our pets next in line for weight-loss drugs?

A biotech firm has announced trials for a dog implant that mimics the drugs taken by humans to help tackle obesity

Benzinga

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

596 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.